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Clinical and Economic Effectiveness of an Inpatient
Anticoagulation Service
Muhammad M. Mamdani, Pharm.D., M.P.H., Eric Racine, Pharm.D., Scott McCreadie, Pharm.D.,
Chris Zimmerman, Pharm.D., Tami L. O’Sullivan, Pharm.D., Gail Jensen, Ph.D.,
Paul Ragatzki, M.D., and James G. Stevenson, Pharm.D.
We conducted a prospective cohort study to evaluate clinical and economic
end points achieved by a pharmacist-managed anticoagulation service
compared with usual care (50 patients/group).  The primary therapeutic end
point was the time between starting heparin therapy and surpassing the
activated partial thromboplastin time therapeutic threshold.  The primary
economic end point was the direct variable cost of hospitalization from
admission to discharge.  No significant differences between groups were noted
for the primary therapeutic end point.  Total hospital costs were significantly
lower for patients receiving pharmacist-managed care than for those receiving
usual care ($1594 and $2014, respectively, 1997 dollars, p=0.04).  Earlier start
of warfarin (p=0.05) and shorter hospital stay (5 and 7 days, p=0.05) were
associated with the pharmacist-managed group.
(Pharmacotherapy 1999;19(9):1064–1074)
Venous thromboembolism, specifically, deep
vein thrombosis (DVT) or pulmonary embolism
(PE), is a life-threatening condition resulting in
approximately 300,000 hospitalizations and at
least 50,000 deaths/year in the United States.1–3
It is estimated that direct medical costs alone
cost the country’s health care system at least
$600 million annually. It is imperative that
treatment be initiated quickly and effectively to
avoid fatal complications.  Agents of choice for
immediate and long-term anticoagulation are
intravenous unfractionated heparin (UFH) and
oral warfarin, respectively, for DVT and PE.4
Although much interest has been expressed in
subcutaneous low-molecular-weight heparin
(LMWH) for outpatient treatment of DVT,
substantial numbers of patients with proximal
DVT require inpatient treatment.
Failure to achieve adequate anticoagulation
with UFH within the first 24 hours of therapy
may compromise care and put the patient at
5–15 times the relative risk of developing
recurrent thrombi.5, 6 Unfortunately, UFH’s
complex pharmacokinetics result in tremendous
variability in dosing.7–9 In 1995, a drug use
evaluation of UFH therapy conducted at the
Detroit Medical Center (DMC) revealed that only
42% of patients evaluated surpassed the
therapeutic threshold within 24 hours of starting
therapy with a 5000-U bolus followed by a 1000-
U/hour continuous infusion.  A weight-based
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nomogram10 is superior to standard dosing in
calculating initial dosages that rapidly exceed the
therapeutic threshold and achieve a greater
proportion of therapeutic activated partial
thromboplastin times (aPTTs).10, 11
Once the therapeutic threshold of UFH is
surpassed, often within the first 2 days of therapy
in standard practice, oral warfarin is considered
for at least 3 months.  However, complex
pharmacokinetics, potential adverse effects, and
numerous drug-drug interactions complicate its
administration and may lead to inappropriate
dosages, unnecessarily long hospitalization, and
avoidable adverse events.  Clinical evidence
suggests that starting warfarin on the same
day as UFH is safe and effective,12 having the
potential to shorten the duration of heparin
therapy and length of hospital stay.  Applying a
flexible induction nomogram for warfarin dosing
is safe and effective.13
We evaluated clinical and economic end points
achieved by a comprehensive pharmacist-
managed anticoagulation consult service.  Results
were compared with those in patients receiving
usual care.  It was hypothesized that the
anticoagulation service would result in improved
clinical end points, reduced length of stay, and
lower total cost of hospitalization.
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Adjusted Raschke Heparin Weight-Based Nomogram10
Initial dose: 80 U/kg bolus, then 18 U/kg x hr
aPTT < 37 sec (< 1.2 x control): 80 U/kg bolus, then increase
infusion rate by 4 U/kg x hr
aPTT 37 to 47 sec (1.2–1.5 x control): 40 U/kg bolus, then increase
infusion rate by 2 U/kg x hr
aPTT 48–71 sec (1.5–2.3 x control): No change
aPTT 72–93 sec (2.3–3 x control): Decrease infusion rate by 2 U/kg
x hr
aPTT > 93 sec ( > 3 x control): Hold infusion 1 hr, then decrease
infusion rate by 3 U/kg x hr
Adjusted Fennerty Warfarin Dosing Nomogram19
Day INR Warfarin Dose (mg)
1 < 1.4 10.0
2 < 1.8 10.0
1.8 1.0
> 1.8 0.5
3 < 2.0 10.0
2.0–2.1 5.0
2.2–2.3 4.5
2.4–2.5 4.0
2.6–2.7 3.5
2.8–2.9 3.0
> 3.0 0
Predicted Dose
4 < 1.4 > 8.0
1.4 8.0
1.5 7.5
1.6–1.7 7.0
1.8 6.5
1.9 6.0
2.0–2.1 5.5
2.2–2.3 5.0
2.4–2.6 4.5
2.7–3.0 4.0
3.1–3.5 Miss next day’s dose, then give 3.5 mg
3.6–4.0 Miss next day’s dose, then give 3.0 mg
4.1–4.5 Miss next day’s dose, then give 2 mg
> 4.5 Miss 2 days’ doses, then give 1 mg
Figure 1. Adjusted nomograms for managing heparin and warfarin therapy.
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Methods
Study Design
A prospective, observational cohort study was
conducted to reflect real-world practice and
assess effectiveness rather than efficacy of the
anticoagulation service.  The study was conducted
simultaneously at two teaching hospitals in the
DMC.
A 24-hour, 7-day/week pharmacist-managed
anticoagulation service was established in May
1996 by the Department of Pharmacy Services to
provide dosing and monitoring of UFH and
warfarin therapies at the request of a physician.
The Raschke weight-based UFH dosing nomo-
gram6 and a modified Fennerty flexible induction
warfarin nomogram13 were approved by the
institutions’ Pharmacy and Therapeutics and
Medical Executive Committees (Figure 1).
Pharmacists could deviate from the nomograms
based on professional judgment.  Once
consulted, they also could adjust UFH and
warfarin dosages and order appropriate
monitoring tests.  The UFH dosing nomogram
was modified by the hematology laboratory to
correspond to ranges of values of the original
weight-based nomogram.6 Before implementation,
all clinical pharmacists were trained through a
certification process in UFH and warfarin
therapeutics and dosing strategies.  Health care
professionals were informed of this service
through in-service programs conducted by
pharmacists and by written notification.
Patients
Patient data were collected sequentially from
medical charts as a convenience sample until 50
evaluable patients in each group were identified
from June 1996–April 1997.  Patients were
considered eligible if they were admitted for
treatment of a DVT or PE and received intravenous
UFH.  Exclusion criteria were thrombolytic
therapy, LMWH, subcutaneous adjusted-dose
UFH, thrombectomy or embolectomy, less than
24 hours of intravenous heparin administration,
delay of greater than 48 hours from hospital
admission to start of heparin therapy, discharge
against medical advice, and events unrelated to
anticoagulation therapy that would unnecessarily
prolong hospital stay by more than 48 hours.
Demographic information recorded for each
patient included actual body weight, age, gender,
race, and smoking history.  Baseline aPTT,
prothrombin time (PT), hemoglobin, hematocrit,
platelet count, risk factors for thrombosis and
bleeding, discharge diagnosis related to heparin
therapy, medical service providing patient care,
comorbidity, and frequency of adverse events
were also noted.  Risk factors for thrombosis were
defined as concurrent diagnosis of malignancy,14, 15
history of venous thromboembolism or disorder
associated with thromboembolism (e.g.,
documented protein C deficiency, antiphospholipid
antibody syndrome),16 and prolonged immobi-
lization due to traumatic spinal cord injury (e.g.,
paraplegia).17
Risk factors for bleeding included history of
stroke or surgery within 14 days before
admission, history of peptic ulcer disease or
gastrointestinal or genitourinary hemorrhage,
and platelet count below 100 x 103/mm3.18 Major
hemorrhage was defined as overt bleeding with
one of the following criteria:  decrease in
hemoglobin of more than 2 g/dl, transfusion of 2
U or more of blood, or location of hemorrhage in
the retroperitoneum, cranium, or prosthetic
joint.  Minor hemorrhage was defined as overt
bleeding that did not meet preceding criteria.18
Comorbidity was assessed using the Charlson
comorbidity index.19 Heparin-induced thrombo-
cytopenia was defined as a decrease in platelet
count to less than 100 x 103/mm3 or, in patients
whose baseline platelet count was below that
value, a drop of 50% from baseline.5, 6 All
subsequent aPTTs, platelet counts, hemoglobins,
hematocrits, international normalized ratios
(INR), and heparin and warfarin dosage
adjustments were recorded with respective times
of collection.
Economic and efficiency information recorded
for each patient included hospital length of stay,
UFH and warfarin dosages and duration, number
of aPTT and INR values to monitor anticoagulant
therapy, estimated pharmacist time involved in
providing patient care, interval between blood
sampling for aPTT measurements and UFH
dosage adjustment when necessary, total cost of
hospitalization as determined by the department
of finance, and compliance with the nomograms.
Therapeutic and Economic End Points
The primary therapeutic end point was time
elapsed between starting UFH therapy and
surpassing the therapeutic threshold, which was
defined as an aPTT of 48 seconds.  Secondary
therapeutic end points for UFH therapy were
time elapsed before achieving an aPTT within the
defined therapeutic range; proportion of
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subtherapeutic, therapeutic, and supratherapeutic
aPTT values (blood samples drawn < 4 hrs after
dosage adjustments were excluded); and number
of aPTT values/patient.  Secondary therapeutic
end points for warfarin therapy were duration
between starting warfarin and starting UFH
therapy, proportion of patients with a therapeutic
INR on day 5 of warfarin therapy and at
discharge, and number of INR values/patient
receiving warfarin.  Nomogram compliance and
adverse events associated with anticoagulation
therapy were also assessed.
Compliance with the UFH nomogram was
defined as absence of deviations in initial bolus
doses, maintenance infusion rates, and sub-
sequent dosing.  Compliance with the warfarin
nomogram was defined as absence of any
deviation with respect to warfarin dosing.
The primary economic end point was the direct
variable cost of hospitalization from admission to
discharge, as determined by the central finance
department using a cost accounting system.
Secondary economic end points were length of
hospital stay and opportunity cost of pharmacist
time involved in providing clinical services in the
pharmacist-managed anticoagulation group.
Opportunity cost can be defined as the amount
that a resource could earn in its highest valued
alternative use; it is the value of the alternative
that must be foregone when something is
produced.20 Since clinical pharmacists are
routinely involved in cost-saving interventions
and are paid an annual salary irrespective of these
interventions, an opportunity cost is incurred.  It
was estimated that hourly savings due to drug
interventions for the average pharmacist at our
institution range from $10.71–48.28 with a
weighted average estimate of approximately
$16.41/hour.21 In contrast to opportunity cost,
the pharmacist’s salary also could be used to
assess the economic impact of the service.  This
was taken into consideration through sensitivity
analyses that encompassed these values.
The impact of the anticoagulation service on
pharmacist time and workload in the
anticoagulation service was evaluated by a
written questionnaire that asked clinical
pharmacists to estimate the amount of time
involved daily in providing clinical services to
patients with venous thromboembolism.  Areas
of interest were amount of time spent writing
notes in medical records, writing orders for
laboratory tests and changes in regimens,
checking laboratory values, consulting with the
medical team regarding patient care issues, and
miscellaneous activities not covered by the
questionnaire (e.g., reviewing patient histories,
handling pump failure, communicating with
nurses about interventions).  All cost data were
based on nominal dollars.
The primary a priori economic model
considered two gross measures of economic
activity—opportunity cost of lost pharmacist
intervention time and cost of hospitalization—
based on the equation below:
Costpharmacist-managed care =
costhospitalization + costpharmacist intervention time
Costusual care = costhospitalization
Measurements
Heparin sodium (porcine derived; Wyeth
Ayerst, Elkins-Sinn Division, Chicago, IL) was
diluted in 5% dextrose solution and administered
with infusion pumps.  All blood specimens for
aPTT and INR values were collected in siliconized
Vacutainer tubes (Becton-Dickinson, Rutherford,
NJ) containing buffered citrate.  The IL Test
aPTT-C Activated Partial Thromboplastin Time
and IL Test PT-Fibrinogen thromboplastin
reagents (Instrumentation Laboratory Co.,
Lexington, MA) were used to determine aPTT
and INR values, respectively, on automated
coagulation systems (ACL 3000; Instrumentation
Laboratory Co.).  The thromboplastin reagent
had an international sensitivity index of 1.99.
Statistical Analyses
The independent samples t test and the Mann-
Whitney U test were used to detect differences
between groups for parametric and nonparametric
continuous variables, respectively.  The x2 and
Fisher’s exact tests were used to compare discrete
variables where appropriate.  Kaplan-Meier time-
to-event analysis was conducted to assess
differences between groups with respect to the
time required to surpass the therapeutic
threshold and to obtain an aPTT within the
therapeutic range.  Bivariate correlations using
Pearson’s correlations for parametric data and
Spearman’s rho statistic for nonparametric data
were conducted to assess relationships between
clinical and economic variables and aid in
constructing efficient regression models.
Multiple regression models were constructed and
tested through forward selection and backward
elimination methods to examine potential
determinants of UFH therapy requirements, time
of starting warfarin therapy relative to UFH
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therapy, length of stay, and total hospitalization
cost.  Both methods yielded identical final
models.  The SPSS, version 6.1, was used to
conduct the analyses.  Sensitivity analyses were
performed with a computer software program
(DATA; TreeAge, Boston, MA).
A 10,000-iteration Monte Carlo simulation
using Latin hypercube sampling was conducted
to assess total variability in economic data
observed for the primary economic model using a
software package (Crystal Ball; Decisioneering,
Boulder, CO).  Best-fit distributions were
generated using available data for cost of
hospitalization, length of stay, pharmacist time
requirements, and hourly savings from inter-
ventions by pharmacists had the service not
existed.  Correlations among variables were
incorporated into the model when available.
A power analysis assuming a significance level
of a equal to 0.05 and power of at least 90%
revealed that 100 patients (50/group) would be
required to detect expected differences in
primary clinical and economic end points.
Results
Patient Characteristics
To obtain 50 patients for analysis in the usual
care group, 92 charts were reviewed.  Forty-two
patients were excluded for the following reasons:
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Table 1.  Baseline Patient Demographics 
Usual Care Pharmacist-
Characteristic (n=50) Managed Care (n=50) p Value
Mean age, yrs 60.4 (19.1) 56.7 (18.3) 0.50
Median weight, kga 73.2 (29.4) 79.8 (30.5) 0.12
Men (%) 42 44 0.84
Race (%) 0.22
African-American 72 86
Caucasian 22 10
Other 6 4
Smokers (%) 32 40 0.36
Thrombosis tendency (%) 70 64 0.52
Bleeding tendency (%)b 14.3 16.7 1.0
Baseline hematology laboratory resultsc
Median aPTT, sec 26.1 (5.6) 27.3 (6.2) 0.12
Median PT, sec 12.7 (1.5) 13.1 (1.6) 0.31
Median hemoglobin (mg/dl)d 0.20
Men 13.7 (3.6) 12.0 (3.3)
Women 12.4 (2.5) 12.6 (1.9)
Median hematocrit (%)d 0.22
Men 40.3 (11.7) 36.4 (10.1)
Women 38.3 (7.1) 37.8 (6.3)
Median platelet count, x 103/mm3 223 (102) 226 (123) 0.37
Diagnosis (%) 0.66
PE 16 20
DVT 76 68
PE and DVT 8 12
Patient service (%) 0.35
Internal medicine 82 92
Oncology 4 2
Surgery 4 4
Other 10 2
Median index of comorbidity 2 2 0.56
PE = pulmonary embolism; DVT = deep vein thrombosis.
Numbers in parentheses are SDs for mean values and interquartile ranges for median values.
aForty-eight patients in the usual care group were evaluable.
bForty-nine and 48 patients, respectively, in the usual care and anticoagulation service groups were evaluable.
cBaseline hematology laboratory data were available for 45 and 46 patients, respectively, in the usual care and
anticoagulation service groups.
dTwenty men were evaluable in each treatment group; 24 and 25 women, respectively, were evaluable in the usual care and
anticoagulation service groups.
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therapy with LMWH (3 patients) or subcutaneous
UFH (5) for primary treatment, receipt of a
thrombolytic agent (11), less than 48 hours of
UFH therapy (6), prolonged hospitalization
unrelated to anticoagulation therapy (5),
premature discharge against medical advice (2),
no anticoagulants (3), physician intentionally not
desiring a therapeutic aPTT (1), misdiagnosis
(2), immediate death (2), and thrombectomy (2).
For the pharmacist-managed group, 83 charts
were reviewed before 50 evaluable patients were
obtained.  Thirty-three patients were excluded
for the following reasons:  less than 48 hours of
UFH therapy (10), delay of more than 48 hours
administering UFH from time of admission (2),
prolonged hospitalization unrelated to
anticoagulation therapy (4), premature discharge
against medical advice (4), misdiagnosis (4),
absence of laboratory or drug information in the
medical record (3), consultation of the
anticoagulation service and subsequent
discontinuation before completion of therapy (3),
thrombectomy (2), and embolectomy (1).
Baseline demographics data for both groups
were similar (Table 1).
Therapeutic Outcomes
UFH Therapy
The anticoagulation service was consulted after
starting UFH therapy for 70% of patients enrolled
in the pharmacist-managed group.  The
proportion of patients surpassing the therapeutic
threshold within 12, 24, and 48 hours of starting
UFH was not significantly different between
groups (Table 2).
The pharmacist-managed group had a
significantly greater proportion of therapeutic
aPTT values than the usual care group (47.7% vs
41.5%, p=0.05) and a significantly lower
proportion of subtherapeutic aPTT values (15.8%
vs 21.3%, p=0.03).  Two patients receiving usual
care never achieved a therapeutic aPTT
throughout UFH therapy, compared with none in
the pharmacist-managed group.  The median
amount of time between a blood draw and
response to a nontherapeutic aPTT differed
significantly:  2.8 hours in the pharmacist-
managed group and 4.4 hours in the usual care
group (p<0.001).
In assessing resource use with respect to total
inpatient UFH therapy, two patients (one from
each group) were excluded from the analysis due
to death.  Bivariate analyses revealed age, male
gender, and weight to be significantly associated
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Table 2.  End Points of UFH Therapy
End Point Usual Care Pharmacist-Managed Care p Value
Median initial bolus dose, U 5000 (1000) 5000 (1250) 0.32
Median initial infusion rate, U/hr 1000 (300) 1100 (363) 0.45
Percentage of patients in whom first aPTT was
> Therapeutic threshold 78 84 0.44
Within therapeutic range 18 24 0.46
Percentage of patients surpassing therapeutic threshold within
12 hrs of starting heparin 82 88 0.40
24 hrs of starting heparin 88 92 0.74
48 hrs of starting heparin 92 98 0.36
Median time to first therapeutic aPTTa, hrs 25.3 (29.3) 23.6 (24.4) 0.14
Median infusion rate of first therapeutic aPTT, U/hra 1000 (388) 1000 (400) 0.82
Number of aPTT values examined 489 476
Percentage of aPTT values < 0.001
Subtherapeutic 21.3 15.8 0.03
Therapeutic 41.5 47.7 0.05
Supratherapeutic 37.2 36.6 0.83
Median duration of UFH therapy/pt, daysb 4.8 (3.04) 4.9 (2.05) 0.92
Median amount of UFH/pt, Ub 112,300 (87,775) 124,750 (71,575) 0.84
Median number of aPTT values ordered/ptb 9 (7) 9 (4) 0.78
Median number of dosage adjustments/ptc 4 (3) 4 (3) 0.42
Median time from blood draw to regimen adjustment if necessary, hrsb 4.4 (2.9) 2.8 (1.5) < 0.001
Numbers in parentheses are interquartile ranges.
aTwo patients receiving usual care did not achieve a therapeutic aPTT or reach a therapeutic state.
bOne patient in each group was excluded from the analysis due to death.
cNo regimen adjustments were made in two patients receiving usual care.
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with UFH requirements (r = -0.327, p=0.001; r =
0.501, p<0.001; r = 0.291, p=0.004, respectively).
After controlling for age and weight in
multivariate analyses, gender was no longer
significantly associated with UFH requirements
at the a = 0.05 level, but a trend for greater
requirements in men persisted (b = 0.169,
p=0.064).  Age had an inverse relationship to
UFH requirement (b = -0.215, p=0.02) and
weight had a directly proportional relationship (b
= 0.400, p<0.001).  These three factors accounted
for approximately 29% of variation in amount of
UFH required/patient (adjusted R2 = 0.289).
Warfarin Therapy
Ninety percent of patients in the pharmacist-
managed group and 76% in the usual care group
received warfarin (p=0.10; Table 3).  A
significantly greater proportion of patients
received the drug within 2 days of UFH initiation
in the pharmacist-managed group than in the
usual care group (82% vs 63%, p=0.05).  Multiple
regression analysis examining the influence of
age, gender, diagnosis, amount of time to reach a
therapeutic aPTT, bleeding risk, and comorbidity
index on the day of starting warfarin relative to
UFH revealed no significant associations.
Nomogram Compliance in the Pharmacist-Managed
Group
Of the 196 UFH dosage adjustments made after
initial dosing, 86 (43.9%) were consistent with
the UFH nomogram.
For the 45 patients receiving warfarin, no
deviations from the nomogram were observed for
14 patients (31.3%).  Of the 31 patients in whom
deviations occurred, the nomogram did not apply
to 9.  Seven of these patients required greater
than 10 mg/day to attain a therapeutic INR (the
nomogram does not account for such patients),
one had previously received warfarin and the
maintenance dosage was known and given, and
one had warfarin held due to a minor bleeding
event.
Adverse Events
Major bleeding did not occur in any patient
receiving pharmacist-managed care but did occur
in two (4%) receiving usual care.  One of these
patients had a therapeutic aPTT at the time of
bleeding and was not receiving warfarin.  The
other patient whose INR rose to 16.8 and whose
aPTT was slightly supratherapeutic at the time of
bleeding, suffered a major intracerebral bleed that
resulted in death.  One patient in the pharmacist-
managed group died due to a PE that was
suspected to have developed during hospital-
ization.  The patient was not receiving warfarin
and the aPTT was slightly subtherapeutic at the
time of death.  No statistically significant
differences were observed between groups with
respect to minor bleeding complications (8%
each group).  No patient in either group
developed thrombocytopenia.
Economic Outcomes
Cost of Hospitalization
In assessing differences in cost of
hospitalization, accurate financial data were
readily available for 89 of the 100 patients, after
excluding 2 deaths.  Median cost was
approximately 21% less for the pharmacist-
managed (n=42) group than for the usual care
(n=47) group ($1594 and $2014, respectively,
p=0.04).  Bivariate analyses revealed length of
stay, day starting warfarin therapy, and
proportion of aPTT values above therapeutic
threshold to be statistically significantly
associated with cost of hospitalization (r = 0.61,
p<0.001; r = 0.328, p=0.005; r = -0.276, p=0.009,
respectively).  The proportion of aPTT values
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Table 3.  Therapeutic End Points of Warfarin Therapy
End Point Usual Care Pharmacist-Managed Care p Value
Percentage of patients treated with warfarin 76 90 0.10
Percentage of patients in whom warfarin was begun within 2 days of heparin 63 82 0.05
Therapeutic INRa
By day 5 of therapy (%) 40 47 0.51
At discharge (%) 58 71 0.21
Median duration of warfarin therapy, daysb 6 (3.5) 5 (2) 0.49
Median dose of warfarin at discharge, mgb 5 (4.4) 5 (2.5) 0.10
Numbers in parentheses are interquartile ranges.
aTwo patients receiving usual care were excluded, one  due to death, one due to lack of warfarin monitoring.
bOne patient receiving usual care was excluded from the analysis due to death.
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above therapeutic threshold and day of starting
warfarin relative to UFH were inversely
correlated (r = -0.326, p=0.005).  In multivariate
analyses, only length of stay was significantly
associated with cost of hospitalization and
accounted for approximately 47% of the observed
variation (adjusted R2 = 0.466, b = 0.687,
p<0.001 for length of stay).
Length of Hospital Stay
Median overall length of stay, excluding two
deaths, was significantly shorter for the
pharmacist-managed group than for the usual
care group (5 and 7 days, respectively, p=0.05).
Bivariate analyses for the 89 patients with
sufficient financial data revealed weight, day of
starting warfarin relative to UFH initiation, and
comorbidity index to be statistically significantly
associated with length of stay (r=0.263, p=0.013;
r=0.353, p=0.002; r=0.221, p=0.038, respectively).
On multivariate analyses, however, only weight
and day of starting warfarin therapy had a
significant, positive relationship to length of stay
and accounted for approximately 24% of the
observed variability (adjusted R2 = 0.235; b =
0.254, p=0.01 for weight, b = 0.422, p<0.001 for
day of starting warfarin).
Analysis of patients excluded from cost
assessments showed no significant differences
between groups regarding length of stay.
Pharmacist Opportunity Cost
Average daily total time attributable to
providing anticoagulation management services
by pharmacists was estimated to be
approximately 1 hour/patient (range 33–80 min,
Table 4).  Given an opportunity cost of $16.41
($10.71–48.28)/hour from lost interventions for
a median of 5 days/patient, it was estimated that
$82 would be lost in providing services for the
average patient managed in the anticoagulation
service group.  Since the difference in median
cost of hospitalization between groups was $420,
a benefit:cost ratio of 5:1 for providing the
service was calculated and an approximate net
savings/patient of $338 (17% reduction in net
costs/patient) was expected.
One-way sensitivity analysis showed cost
savings in favor of pharmacist management if the
average patient required less than an average of 5
hours of care/day. Two-way sensitivity analysis
examined the interaction between amount of
time required/day/patient and hourly savings that
would have been realized had the pharmacist-
managed service not been implemented (i.e.,
opportunity cost; Figure 2).  Results of the Monte
Carlo simulation were consistent with our
original analyses and indicated a mean net
savings/patient of $340 (95% confidence interval
[CI] for the mean $313–368) and an overall
benefit:cost ratio of 5.0.
Discussion
The results of this study indicate possible
significant clinical and economic benefits in
implementing a pharmacist-managed anti-
coagulation service for inpatient treatment of
DVT or PE relative to usual care.  A greater
proportion of therapeutic aPTT values, earlier
start of warfarin therapy relative to UFH therapy,
faster response to nontherapeutic aPTT values,
shorter hospitalization, and lower total hospital
costs were significantly associated with the
pharmacist-managed group.  A major deter-
minant of hospital length of stay and, in turn,
cost of hospitalization was the day of starting
warfarin, if indicated, relative to UFH initiation.
Starting warfarin earlier was associated with a
shorter hospital stay.  The day of starting warfarin
was inversely related to the proportion of aPTT
values above the therapeutic threshold, both of
which were significantly more favorable in the
pharmacist-managed group.  Given an annual
admission of approximately 300 patients with a
primary diagnosis of DVT or PE between the two
institutions and an estimated reduction in net
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Table 4.  Composition of Anticoagulation Service Workloada
Shift
Activity (%) Morning (n=18) Afternoon (n=6) Midnight (n=4)
Writing progress notes in patient charts 31 31 34
Writing orders and changing anticoagulation regimens 24 31 31
Checking laboratory results 17 17 18
Consulting with medical team regarding patient issues 28 21 17
Total estimated time, minutes (range) 22 (12–62) 19 (12–52) 16 (22–47)
aFigures represent estimated daily times as a proportion of total daily times in the respective work shift spent by clinical pharmacists in caring
for an average patient for whom clinical services were provided in the nomogram-based care group.
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costs of 17% in the pharmacist-managed group,
annual savings of approximately $101,000 may
be realized from providing anticoagulation
services.
Although these findings are encouraging and
support implementation of similar services,
several methodologic limitations of this study
must be addressed before generalizations can be
made.  An observational design was chosen for
its ease of implementation and real-world appeal.
An observational study collects data from an
existing system and does not intentionally
interfere with the operation of the system.22 As
with any observational design that does not
employ blinding or randomization, the issues of
bias, confounding, and chance must be
explored.23
Selection bias may result in an uneven
allocation of patients to study groups and unfair
comparison.  Baseline patient demographics,
however, indicate reasonable comparability
between groups with respect to measured
variables.  Information bias may result in
different data collected between groups and
threaten a valid analysis.  All clinical data were
collected with a standard form to allow for
consistent, objective information.  Since patient
data were collected as a convenience sample
through chart review based on availability, it is
possible that differential chart selection may have
occurred.  All efforts were made, however, to
include all sequentially available charts regardless
of study group status.  If a sequential chart was
excluded, the reason for exclusion was
documented and reviewed to ensure legitimate
exclusion according to a priori exclusion criteria.
Since the anticoagulation service was provided
on a consult basis, it is possible that physicians
consulted pharmacists according to perceived
difficulty in managing the patient themselves.
The impact of this potential phenomenon on our
results is difficult to evaluate.  Financial data
were reported independently by the finance
department without knowledge of study group
designation.
Our results may be significantly confounded by
a cross-contamination effect.22 Nomograms were
given to requesting physicians regardless of their
use of the anticoagulation service.  Pharmacists
also provided educational services to other
clinicians regarding the nomograms.  Although
prestudy data from 1993 revealed that only 42%
of patients evaluated surpassed the therapeutic
threshold within 24 hours of starting heparin
therapy, the results of the current study indicate
that this statistic for the usual care group more
than doubled to 88%.  Furthermore, 82% of
heparin orders were begun with a traditional
bolus dose of 5000 U and a continuous infusion
of 1000 U/hour according to 1993 data compared
with 44% in the usual care group for this study.
Although these contrasts may represent natural
progression in physician practice patterns, they
may be more likely related to heightened
awareness and use of nomograms.  Given this
contamination effect, clinical differences between
study groups may have been weakened.
Sample sizes were calculated based on expected
clinical differences between groups according to
previous studies.6, 11 Significant differences in
certain clinical end points may not have been
found due to confounding effects.  Differences in
less common outcomes, for example, major
bleeding, also may not be apparent due to the
small sample.  Larger samples are necessary to
detect such important differences.
Compliance with nomograms in the
pharmacist-managed group was poor.  Although
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Figure 2. Two-way sensitivity analysis has two shaded
areas, each corresponding to a different region of
preference.  The line separating the areas represents
economic break-even points for various combinations of the
two variables.  At these points, costs associated with either
strategy will be approximately the same.  For example, if it
were expected that 2 hours/patient/day would be required at
an opportunity cost of $30/hour in providing
anticoagulation services, this combination of values would
fall in the region of preference corresponding to pharmacist-
managed care.  In this case, cost savings would be realized
from such a service relative to usual care.
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deviation from the nomograms was discouraged,
clinical judgment by the pharmacist was
recommended whenever uncertainty arose.
Physicians consulted the anticoagulation service
after initial UFH bolus dosing and establishment
of continuous infusion rate for approximately
70% of patients, leading to immediate,
uncontrollable deviation from the nomogram.  As
a result, data analysis for the pharmacist-
managed group during the first 24 hours may be
inaccurate.  Although these outcomes reflect real-
world practice, efforts must be made to improve
nomogram compliance and enhance earlier
nomogram implementation through the
anticoagulation service.
The results may be limited to the particular
nomograms.  Since compliance was poor and a
significant proportion of dosage adjustments
were based on pharmacists’ clinical judgment
rather than nomograms, qualitative factors
characteristic of clinicians at a particular
institution must be taken into consideration.
Generally, clinicians are most likely to accept
guidelines that are easy to implement and that
increase efficiency.24 Much discussion has
evolved around the initial dosing of warfarin.
Although many experts now recommend 5 mg
rather than 10 mg, this information was not
available at the time the study was conducted.
The pharmacists were trained, however, to
deviate from the nomogram and give a 5-mg
starting dose in elderly patients and those
receiving drugs with a high interaction potential
with warfarin.
Estimation of pharmacist time was based on a
questionnaire rather than time-motion studies.
The opportunity cost was assessed using data
derived from an established computerized system
at our institutions.21 Both methods may be fairly
inaccurate and highly variable.  Sensitivity
analyses were conducted to assess the impact of
this variability on the results more accurately and
strengthen the economic findings.  Also, patients
in whom a diagnosis of DVT or PE was ruled out
were excluded from the analysis.  Although these
patients required a limited amount of service
time until the diagnosis was ruled out, sensitivity
analyses revealed that this should not
significantly affect the economic findings.
Ability to generalize our findings may be
limited depending on the institution, disease
states treated, and nomograms used.  All
institutions must assess the feasibility of
implementing a similar anticoagulation service.
Such a service may be provided more practically
by institutions that are well staffed with trained
pharmacists to provide daily, 24-hour service.
Commitment from leadership, workload
demands, cooperation with other health care
personnel, institution environment, and potential
costs all must be considered before such an
initiative can be undertaken.  Other health care
professionals, for example nurses,6 have
successfully implemented such a practice with
clinical benefits.  Support of the coagulation
laboratory also may be a significant
consideration.  Finally, our results pertain to
patients diagnosed with DVT or PE and may not
be extrapolated to those with other disorders.
Although much interest has been expressed in
subcutaneous LMWH for outpatient treatment of
DVT25, 26 and PE, approximately one-half of
patients with proximal DVT may not be eligible
for such treatment in a typical environment and
may require inpatient treatment based on trial
criteria.27 Such patients would include
intravenous drug abusers, those who are
noncompliant, and patients with bleeding
disorders, complex thrombosis, or poor access to
hospitals.  Depending on the nature of the
institution, such a service may be more valuable
if a significant proportion of patients require
inpatient treatment.
Despite these limitations, our findings suggest
potential clinical and economic benefits
associated with a pharmacist-managed anti-
coagulation service relative to usual care.
Continual monitoring of both clinical and
economic outcomes after establishing such a
service is essential in ensuring its real-world
effectiveness and in identifying areas for
improvement in patient care.
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